Good afternoon and welcome to Markets Desk, your midday read on what's moving and why.
Biotech is back in a meaningful way. Clinical trial wins, a pickup in merger and acquisition activity, and a new wave of drug development technologies are pulling capital back into the sector. Analysts are pointing investors toward targeted ETFs and select names riding the innovation cycle rather than chasing the broad rally.
Shifting to crypto, BitMEX co-founder Arthur Hayes has closed out directional trading positions across his Maelstrom portfolio, with on-chain analysts tracking roughly twenty-six million dollars in token sales. Hayes cited rising macroeconomic and geopolitical uncertainty as his rationale for stepping back, offloading Ethereum, Ethena, Uniswap, and several other positions. When a trader of his profile moves to cash, the market pays attention.
And on the growth equity side, Nebius is drawing eyes with four hundred fifty-four percent revenue growth in the second quarter, outpacing its neocloud competitors by a considerable margin. The catch is valuation — the stock trades at forty-six times sales, making it the richest name in an already expensive cohort. Growth is real, but the price for entry reflects every bit of it.
That's the tape. Markets Desk, signing off the floor.
